This is the authors' abstract. We don't add key points for this paper.
Current evidence suggests substantial increases in dementia numbers across the world [1], although there is evidence in some countries of age for age reductions in both prevalence and incidence across time [2].Thinking about future directions for dementia research, it is important to incorporate our understanding of global challenges for contemporary and future populations.We know that a generalized phenomenon of population aging is occurring across the globe, and that in low-and middle-income countries, many of the diseases associated with affluence are rising in incidence, identified by both the UN and WHO as concerns.These population changes do not affect all people equally.For example, health conditions that are risk factors for dementia are both rising (diabetes) and falling (stroke) in high-income countries.The implications for dementia outcomes for populations cannot be assumed as, for example, the complications of diabetes are declining in some populations and differ by population, inequality, and generation [3].In particular, people who are disadvantaged socioeconomically have lives that are shorter than those of richer population groups and are even so at higher risk for dementia [3]-such groups have not, to date, been well served by the major investments in dementia research.There is increasing realization that public health measures will play an important role in the drive to protect world populations from cognitive impairment and dementia, but there is relatively little research in this area, acknowledgement of lack of knowledge (e.g., recent road map) and a wide variability in actions taken to address these in different societies and certainly in their effectiveness.In the public health domain, this special issue of PLOS Medicine explores potential for addressing reversible factors in varied cultural and socioeconomic environments.Not surprisingly, a "one size fits all" approach does not appear to work.In parallel, research studies published in this special issue also help to advance understanding of genetics and dementia, emphasizing a heterogeneity of risk factors for different individuals and populations.Genetics play a critical role in defining risk for neurodegenerative disorders, particularly for those at familial risk, while helping to select targets for therapies.The systematic study of Alzheimer disease (AD) began seriously in the mid-1980s with the discovery that the major protein in plaques consisted of a 42-amino-acid protein, amyloid-β-42 [4].Subsequently, discovery of genetic mutations in the amyloid precursor protein genes [5], presenilin 1 [6] and presenilin 2 [7], as causes for familial AD supported an amyloid hypothesis for AD, as all of these mutations influenced the production and metabolism of amyloid-β-42.Yet, these mutations are rare in most populations, accounting for less than 2% of AD cases.More than 30
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Brayne et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: